- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Oxidative Medicine and Cellular Longevity
Volume 2013 (2013), Article ID 919313, 9 pages
Nrf2 Is Crucial to Graft Survival in a Rodent Model of Heart Transplantation
1Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ 85721, USA
2Department of Cardiothoracic Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
3Department of Pathology, School of Medicine, Northwestern University, Chicago, IL 60611, USA
4Department of Pathology, The University of Arizona, Tucson, AZ 85724, USA
Received 26 November 2012; Accepted 15 January 2013
Academic Editor: Jingbo Pi
Copyright © 2013 Wei Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Currently, the sole treatment option for patients with heart failure is transplantation. The battle of prolonging graft survival and modulating innate and adaptive immune responses is still being waged in the clinic and in research labs. The transcription factor Nrf2 controls major cell survival pathways and is central to moderating inflammation and immune responses. In this study the effect of Nrf2 levels in host recipient C57BL/6 mice on Balb/c allogeneic graft survival was examined. Importantly, Nrf2−/− recipient mice could not support the graft for longer than 7.5 days on average, whereas activation of Nrf2 by sulforaphane in Nrf2+/+ hosts prolonged graft survival to 13 days. Several immune cells in the spleen of recipient mice were unchanged; however, CD11b+ macrophages were significantly increased in Nrf2−/− mice. In addition, IL-17 mRNA levels were elevated in grafts transplanted into Nrf2−/− mice. Although Nrf2 appears to play a crucial role in graft survival, the exact mechanism is yet to be fully understood.
Heart transplantation is the only restorative technique for end-stage heart failure, and allograft rejection remains a significant barrier to successful transplantation. The immune response to an allograft is an ongoing interchange between the innate and adaptive immune systems, which if left unchecked will ultimately lead to rejection of the transplanted organ. In addition, implanted grafts are recognized as “nonself” by the recipient immune system due to discordant major histocompatibility complex (MHC); what is more, other immunogenic signals such as tissue damage resulting from organ procurement and ischemia/reperfusion damage can also promote host immune responses and graft rejection.
The transcription factor nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) or “Nrf2” is a master regulator of the cellular antioxidant response. Nrf2 promotes cell survival by binding the antioxidant response element (ARE) in the promoter of downstream target genes that promote detoxification of xenobiotics and scavenging of reactive oxygen species (ROS). The benefit of Nrf2 activation has been demonstrated in various pathological states such as diabetes, chemoprevention, and cardiovascular and neurological diseases [1–5].
The role of Nrf2 in mediating cellular inflammation and immunity is rapidly becoming established. Activation of Nrf2 appears to antagonize inflammatory pathways such as TGF1 and NF-B [6, 7]. Nrf2’s influence on survival of transplants (i.e., liver or cardiac stem cells) has been investigated from the side of the donated tissue [8–10]. However, Nrf2 genotype and/or modulation on the side of the recipient host have not yet been investigated. The purpose of the present study was to determine how Nrf2 in recipient hosts affects graft survival in an allogeneic mouse model of heart transplantation.
2.1. Animals and Surgery
Nrf2+/+ (WT) and Nrf2−/− (KO) C57BL/6 mice (described previously ) aged 8–12 weeks were used as recipient mice for heart transplant studies. Six–eight-week-old Balb/c mice were purchased from Jackson Labs and used as donors for heart transplant studies. All animals received water and food ad libitum. Nrf2 WT mice were left untreated or given sulforaphane (SF) (WT + SF) by i.p. injection (12.5 mg/kg body weight) one day prior to transplant and every 48 h after transplant until animals were sacrificed. KO mice were left untreated, or a smaller subset also received SF treatment exactly as described previously to assess the specificity of SF acting via the Nrf2 pathway (data not shown). Recipient animals were sacrificed, and organs were harvested for analysis at day 2 and day 5 after transplant. Additional recipient animals were monitored daily to assess viability of the donor heart by monitoring beating under the skin in the neck. These recipient mice were sacrificed, and organs were harvested for analysis once the graft was no longer viable. A diagram of the study design and animal groups (including N-size) is provided in Figure 1.
The mouse model of cervical heterotopic cardiac allograft was performed using the Heron cuff technique and has been described previously in mice . In brief, the right cervical common carotid artery and external jugular vein in recipient C57BL/6 mice were isolated for anastomosis. Clamps were placed at the most caudal end of the carotid artery and external jugular vein, whereas the cranial ends were ligated and severed. A Teflon “cuff” was placed over the caudal carotid artery and jugular vein, and the Balb/c donor aorta and pulmonary artery were connected to the cannula of the recipient cervical common carotid artery and external jugular vein and were ligated and fixed. Blood supply was immediately resumed by releasing the caudal clamps, and the cervical incision was closed if the transplanted heart was beating well without obvious bleeding. The University of Arizona Institutional Animal Care and Use Committee approved all protocols for animal handling and surgery.
Transplanted donor hearts were formalin fixed and paraffin embedded, and sections were cut at 4 μm thickness for hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) analysis. Hearts stained with H&E were evaluated for general histology and rejection according to the International Society for Heart and Lung Transplantation . Briefly, heart sections from day 2 and day 5 following transplantation were evaluated by a trained pathologist and assessed for the grade of rejection defined as follows: 1R = mild, focal perivascular and/or interstitial infiltrate without myocyte damage; 2R = medium, multifocal infiltrate with myocyte damage; 3R = severe, diffuse polymorphous infiltrate with extensive myocyte damage and/or edema and/or hemorrhage and/or vasculitis; or “Quilty” = inflammation from the outside-in, that is, starting from the epicardium and encroaching on the myocardium, possibly due to infection rather than rejection.
2.3. Flow Cytometry Analysis
Single-cell suspensions of spleen were obtained by mincing the organs through a cell strainer dish and stained according to standard procedures. If not mentioned, all the antibodies were purchased from BioLegend (San Diego, USA). Flow cytometry was performed on a BD FACSCanto or Accuri C6 flow cytometer (BD Biosciences, San Jose, USA). Cell surface staining of CD3, CD4, CD8, B220, NK, NKT, macrophages, and DCs was performed following standard protocols; total splenocytes were stimulated with PMA (50 ng/mL)/Ionomycin (1 μg/mL) (in vitro with monensin) for 4 h; then intracellular staining of FoxP3, IFN-γ, IL17, and IL4 was done using the eBioscience staining buffer. All the data were analyzed using FlowJo software (FlowJo, Ashland, USA) excluding cell doublets.
2.4. RNA Isolation and qPCR
Total RNA was isolated from donor heart tissues using Trizol. RNA quality was assessed using a NanoDrop (Wilmington, DE) where the 260/280 ratios were obtained. Samples with a ratio of 1.7–2.1 were utilized for downstream gene analysis. Approximately 1 μg total RNA from each sample was reverse-transcribed using M-MLV (Promega, Madison, WI), oligo-DT, random primers, and dNTPs from Roche (Indianapolis, IN). cDNA was then diluted ~1 : 25 in nuclease free water to be used for qPCR. All primers used were intron spanning, and gene expression levels were analyzed using TaqMan chemistry with primers and probes designed in Roche’s Universal Probe Library Design Center. All experiments were conducted on a LightCycler 480 (Roche). Relative gene expression was calculated using the 2−ΔΔCT method , and studies were designed according to the MIQE guidelines . For all housekeeping and target genes assessed, standard curves were evaluated on 10-fold serial dilutions of control cDNA to determine reaction efficiency. Where efficiencies between housekeeping and target genes differed >5%, efficiencies could be accounted for in the LightCycler 480 software during analysis of relative gene expression. A complete list of target genes and primers is provided in Table 1. Specificity of primer pairs was evaluated through the use of both no-RT and water template control samples. Only primers that did not amplify more than one product or any product in the no-RT and water controls were used for final experiments.
2.5. Statistical Analysis
One-way ANOVA using the Tukey-Kramer post hoc analysis for differences between means assessed statistical differences between animal groups and time points for survival times and flow cytometry. Data from qPCR was analyzed using relative comparison from the Roche LightCycler software, which is based on the 2−ΔΔCT method. Efficiencies of each primer set were determined by standard curve analysis and considered by the software algorithm for determining relative expression over a housekeeping gene, ornithine decarboxylase (Odc).
3.1. Activation of Nrf2 Prolongs Graft Survival of Heart Transplants in Mice
To examine the role of Nrf2 in heart transplant graft survival, hearts from Balb/c mice were transplanted into C57BL/6 Nrf2+/+ (WT) with or without sulforaphane (WT + SF) treatment or Nrf2−/− (KO) mice. Table 2 illustrates that loss of Nrf2 function in mice results in a significantly shorter survival time of the Balb/c graft when compared to their wild-type counterparts, implying that Nrf2 has a protective role in graft survival. Notably, treatment of recipient Nrf2+/+ mice with the Nrf2 activator SF significantly extended the survival of the graft to nearly 13 days. Figure 2 provides a representative illustration of Nrf2 levels in grafts 2 days after transplantation. Note the minimal Nrf2 expression in a few nuclei of the Balb/c donor hearts transplanted into Nrf2 WT (Figure 2(a)) and KO (Figure 2(b)) mice, whereas Nrf2 expression is increased in grafts where Nrf2 WT recipient mice received SF treatment (Figure 2(c)). It is important to note that treatment with SF in the Nrf2−/− mice showed no effects on overall survival time of the graft (data not shown), indicating that SF treatment protects the heart graft from rejection largely through Nrf2 activation. Therefore, activation of Nrf2 has a great therapeutic potential to prolong graft survival in transplantation.
3.2. Treatment of Recipient Mice with Sulforaphane Delays Transplant Rejection
Donated Balb/c hearts were analyzed at 2 and 5 days following transplantation for histology and rejection classification. A summary of the analysis and complete data presentation is provided in Table 3, and representative images of the pathological histology used to categorize each animal are displayed in Figure 3. In summary, Nrf2+/+ and −/− animals showed some low-grade rejection (see Figure 3(b) for representative image of Grade 1R) at 2 days after transplant as similar levels of lymphocyte infiltration were observed. Remarkably, Nrf2+/+ animals pretreated with SF showed no histological signs of rejection 2 days after transplant (see Figure 3(a) for representative image), suggesting that activation of Nrf2 can delay transplant rejection. However, all animals showed significant signs of graft rejection 5 days following transplant (see Figure 3(c) for representative image of Grade 2R), with Nrf2+/+ animals all displaying signs of “Quilty,” a phenomenon thought to be independent of rejection, showing infiltrate originating from the epicardium and infiltrating inward (see Figure 3(d) for representative image of “Quilty”). These data suggest that activation of Nrf2 with SF is able to delay graft rejection and infiltrates of immune cells for at least the first 2 days after transplant, possibly contributing to the significant increase in overall graft survival observed in these animals.
3.3. Nrf2 Influences IL-17 Production in the Spleen of Recipients
T cells are predominating players for acute graft rejection (for review, see ). To investigate a potential mechanism mediating rejection in the Nrf2 KO mice, we analyzed the T-cell immune responses in the spleens of recipient mice. There were no remarkable differences in the numbers of total T cells (CD3+), CD4+, CD8+, Th1, Th2, Tc1, or Tc2 in the spleens of recipients (Figure 4). However, mRNA levels of the Th17 cytokine and IL-17 were markedly higher in the donated hearts transplanted to KO recipients at 2 days following transplant (Figure 5). Together with the notion that loss of Nrf2 function facilitates heart graft rejection (Table 2), the elevated IL-17 production in the graft likely contributes to the rejection. Consistent with the histological analysis, at 5 days after transplant IL-17 mRNA levels in the donated hearts are elevated in all recipient groups regardless of genotype or treatment, implying that other factors exist in the graft-specific immune response due to the altered Nrf2 function.
3.4. Nrf2 KO Mice Generate a Significantly Greater Macrophage Population in Response to Transplant
Evaluation of spleens from recipient C57BL/6 mice for non-T-cell immune cells revealed a significant elevation in CD11b+F4/80+ macrophages in KO mice (Figure 6(a)), whereas other non-T-cell populations such as NK, DC, and B cells are unchanged regardless of genotype, treatment, or time point after transplantation (Figure 7). These data imply a possible link of elevated macrophage population in the spleens of the KO recipient mice to heart graft rejection. To assess whether this additional macrophage population in the KO animals correlated with increased macrophage infiltration of the graft, we evaluated CD11b expression by IHC, as well as CD11b and F4/80 mRNA expression in the grafts from each animal group. Analysis by IHC for CD11b in formalin-fixed, paraffin-embedded grafts yielded inconclusive results due to minimal positive staining within the graft (data not shown). Additionally, evaluation of mRNA levels of CD11b and F4/80 did not show any notable changes in expression (less than 2-fold) between groups when data were normalized to the Nrf2 WT day 2 group (Figure 6(b)).
Currently heart transplantation is the only option for end-stage heart failure disease, and prolonging graft survival is still the subject of intense research. In this study the effects of Nrf2 on host defense and allogeneic graft survival were examined. Our results support that Nrf2 is required to maintain graft survival and that activation of the Nrf2 pathway could prove to be beneficial in extending the life of the transplanted heart.
The role of Nrf2 in the innate and adaptive immune systems continues to be uncovered. Recently, Nrf2 has been implicated in altering maturation of dendritic cells (DCs) [17, 18]. In addition, activation of Nrf2 in older mice upregulates Th1 immunity by maintaining DC redox equilibrium . Although we did not directly assess DC maturity or costimulatory responses in the current study, no alterations in total DC population were observed in the spleens of Nrf2 WT, KO, or WT + SF treated mice. What is more, activation of Nrf2 by the common food preservative, tert-butylhydroquinone (tBHQ), appears to skew CD4+ T cells toward Th2 differentiation; however, there were no observable differences in CD4+ or Th2+ T cells in any of our treatment groups. In the current study we utilized a well-known Nrf2 activator, the isothiocyanate sulforaphane. One possibility is that the mechanism of action of either or both of these activators could have off-target effects that influence T-cell differentiation through a non-Nrf2-mediated pathway.
Nrf2 KO mice have been shown to suffer from splenomegaly and spleen cell death and inflammation in older age, also resulting in hemolytic anemia caused by increased sequestration of IgG-bound erythrocytes in the spleen . Although loss of Nrf2 has been implicated in other autoimmune disorders , the anemia in the study by Lee et al. was instead damage induced from increased oxidative stress. It is hard to determine whether an underlying immune-mediated anemia in the KO mice in this study could have affected the systemic immune response to graft rejection; however, given the young age of the mice in the present study, it is unlikely.
In the case of bacterial infection and sepsis, Nrf2 has been shown to contribute to mobilizing the immune response and counteract the oxidative stress in monocytes [22, 23]. In fact Nrf2 is critical at modulating an “appropriate” level of inflammatory response so as not to be damaging to the host organs and cells. Loss of Nrf2 dramatically impacts survival during experimental sepsis due to deregulated inflammation and activation of Nrf2 can improve survival . Some evidence of this was seen in the present study where CD11b+ macrophages were significantly elevated in the spleen of Nrf2 KO at 2 days after heart transplantation, indicating a disproportionate innate response in the early days after transplant. However, follow-up analysis by IHC and qPCR could not conclusively provide evidence of increased macrophage infiltration in the Nrf2 KO recipient animals. Nrf2 WT mice when given SF did not display a significantly lower CD11b+ count. One possibility is that Nrf2 activation by SF was able to minimize the innate response to early graft rejection thereby extending the overall graft survival by 5 and 3 days over KO and WT mice, respectively. Taken together, the increased macrophage number in the KO spleens may not result in increased infiltration into the graft; however, increased macrophages in the peripheral lymphoid organs could result in production of additional factors such as cytokines, ROS activity, and stress responses, which lead to the earlier rejection.
An additional avenue worth pursuing in the future of this work is the specific scavenging of ROS that is mediated by the Nrf2 pathway. Ischemia-reperfusion injury is a common issue with organ transplantation and has been shown previously to dictate the rejection response over that of recipient immunity . One explanation of poor transplant tolerance in Nrf2 KO mice could be due to their lack of ability to scavenge ROS. Ischemia-reperfusion injury inherently generates high levels of ROS that establish an environment of inflammation and infiltrating leukocytes. Treatment of recipient Nrf2 WT mice with SF could decrease ROS production and assist in minimizing inflammation as well as altering the chemokine environment in the graft to delay intrusion of recipient immune effectors.
Interestingly, there were only subtle differences between T-cell and non-T-cell populations in the recipient spleens of mice in this study. Although CD11b+ macrophages were the only cell population that reached statistical significance, Th17 cells did trend to being higher in Nrf2 KO mice, which was supported by the overwhelming presence of IL-17 mRNA in grafts taken 2 days after transplant from KO mice. Conversely, IL-17 mRNA was notably reduced in grafts harvested 2 days after transplant from WT mice treated with SF. These data support that though there may not be differences in T-cell differentiation or total population, perhaps trafficking of immune cells is somehow different between Nrf2 WT and KO genotypes.
The work presented here displays the importance of Nrf2 in graft survival in an allogeneic mouse model of heart transplant. These data provide an initial insight into the therapeutic benefit of Nrf2 activation during transplant. Yet more work needs to be done to prove the hypotheses laid forth in this study, as well as to fully interrogate how Nrf2 (and its activation) is able to prolong graft survival upon heart transplant. Though the mechanism is critically important, the implications of using Nrf2 activators in a clinical setting to improve allogeneic graft survival are established by our current work.
Conflict of Interests
The authors have no conflict of interests to disclose, such as financial holdings, professional affiliations, advisory positions, board memberships, patent holdings, and the like, or involvement with any commercial secondary interests.
W. Wu and Q. Qiu contributed equally to this work.
- E. L. Donovan, J. M. McCord, D. J. Reuland, B. F. Miller, and K. L. Hamilton, “Phytochemical activation of Nrf2 protects human coronary artery endothelial cells against an oxidative challenge,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 132931, 9 pages, 2012.
- M. Zhang, C. An, Y. Gao, R. K. Leak, J. Chen, and F. Zhang, “Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection,” Progress in Neurobiology, vol. 100, no. 1, pp. 30–47, 2013.
- H. Zheng, S. A. Whitman, W. Wu et al., “Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy,” Diabetes, vol. 60, no. 11, pp. 3055–3066, 2011.
- G. E. Mann, B. Bonacasa, T. Ishii, and R. C. Siow, “Targeting the redox sensitive Nrf2-Keap1 defense pathway in cardiovascular disease: protection afforded by dietary isoflavones,” Current Opinion in Pharmacology, vol. 9, no. 2, pp. 139–145, 2009.
- M. K. Kwak and T. W. Kensler, “Targeting NRF2 signaling for cancer chemoprevention,” Toxicology and Applied Pharmacology, vol. 244, no. 1, pp. 66–76, 2010.
- C. J. Oh, J. Y. Kim, A. K. Min et al., “Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling,” Free Radical Biology and Medicine, vol. 52, no. 3, pp. 671–682, 2012.
- J. Jiang, Z. C. Mo, K. Yin et al., “Epigallocatechin-3-gallate prevents TNF-α-induced NF-κB activation thereby upregulating ABCA1 via the Nrf2/Keap1 pathway in macrophage foam cells,” International Journal of Molecular Medicine, vol. 29, no. 5, pp. 946–956, 2012.
- X. D. Shen, B. Ke, H. Ji et al., “Disruption of type-I IFN pathway ameliorates preservation damage in mouse orthotopic liver transplantation via HO-1 dependent mechanism,” The American Journal of Transplantation, vol. 12, no. 7, pp. 1730–1739, 2012.
- M. Mohammadzadeh, R. Halabian, A. Gharehbaghian et al., “Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity,” Cell Stress and Chaperones, vol. 17, no. 5, pp. 553–565, 2012.
- N. Gorbunov, G. Petrovski, N. Gurusamy, D. Ray, D. H. Kim, and D. K. Das, “Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells,” Journal of Cellular and Molecular Medicine, vol. 16, no. 1, pp. 174–184, 2012.
- P. Moi, K. Chan, I. Asunis, A. Cao, and Y. W. Kan, “Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the β-globin locus control region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 21, pp. 9926–9930, 1994.
- I. Heron, “A technique for accessory cervical heart transplantation in rabbits and rats,” Acta pathologica et Microbiologica Scandinavica A, vol. 79, no. 4, pp. 366–372, 1971.
- S. Stewart, G. L. Winters, M. C. Fishbein et al., “Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection,” Journal of Heart and Lung Transplantation, vol. 24, no. 11, pp. 1710–1720, 2005.
- S. Fleige, V. Walf, S. Huch, C. Prgomet, J. Sehm, and M. W. Pfaffl, “Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR,” Biotechnology Letters, vol. 28, no. 19, pp. 1601–1613, 2006.
- S. A. Bustin, V. Benes, J. A. Garson et al., “The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments,” Clinical Chemistry, vol. 55, no. 4, pp. 611–622, 2009.
- A. Sánchez–Fueyo and T. B. Strom, “Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs,” Gastroenterology, vol. 140, no. 1, pp. 51.e2–64.e2, 2011.
- H. X. A. Yeang, J. M. Hamdam, L. M. A. Al-Huseini et al., “Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis,and intracellular signaling in dendritic cells,” The Journal of Biological Chemistry, vol. 287, no. 13, pp. 10556–10564, 2012.
- T. Rangasamy, M. A. Williams, S. Bauer et al., “Nuclear erythroid 2 p45-related factor 2 inhibits the maturation of murine dendritic cells by ragweed extract,” The American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 3, pp. 276–285, 2010.
- H. J. Kim, B. Barajas, M. Wang, and A. E. Nel, “Nrf2 activation by sulforaphane restores the age-related decrease of TH1 immunity: role of dendritic cells,” Journal of Allergy and Clinical Immunology, vol. 121, no. 5, pp. 1255.e7–1261.e7, 2008.
- J. M. Lee, K. Chan, Y. W. Kan, and J. A. Johnson, “Targeted disruption of Nrf2 causes regenerative immune-mediated hemolytic anemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9751–9756, 2004.
- J. Li, T. D. Stein, and J. A. Johnson, “Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice,” Physiological Genomics, vol. 18, pp. 261–272, 2004.
- S. A. Rushworth, X. L. Chen, N. Mackman, R. M. Ogborne, and M. A. O'Connell, “Lipopolysaccharide-induced heme oxygenase-1 expression in human monocytic cells is mediated via Nrf2 and protein kinase C,” The Journal of Immunology, vol. 175, no. 7, pp. 4408–4415, 2005.
- S. A. Rushworth, D. J. MacEwan, and M. A. O'Connell, “Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes,” The Journal of Immunology, vol. 181, no. 10, pp. 6730–6737, 2008.
- R. K. Thimmulappa, R. J. Fuchs, D. Malhotra et al., “Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils,” Antioxidants and Redox Signaling, vol. 9, no. 11, pp. 1963–1970, 2007.
- G. Chalasani, Q. Li, B. T. Konieczny et al., “The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response,” The Journal of Immunology, vol. 172, no. 12, pp. 7813–7820, 2004.